Table 1.
Ongoing clinical trials registered at Clinicaltrials.gov in which A2A or A2B receptors are targeted to combat malignancies.
| Target * | +/− Combination Therapy | Company /Institution | Cancer Type | Clinicaltrials.Gov Identifier | Study Phase |
|---|---|---|---|---|---|
| A2AR | Inupadenant + EOS-448 (anti-TIGIT mAB) | iTeos Therapeutics | AST | NCT05060432 | 1, 2 (NR) |
| A2AR | Ciforadenant +/− atezolizumab (mAb against PD-1) | Corvus Pharmaceuticals, Inc. | Prostate (advanced/incurable) | NCT02655822 | 1, 1b (R, OL) |
| A2AR | PBF-509 +/− antibody against PD-1 | Palobiofarma SL | NSLC (advanced) | NCT02403193 | 1, 2 (NR, OL) |
| A2AR | Taminadenant + Spartalizumab (mAb against PD-1) + DFF332 (Hif2α inhibitor) | Novartis Pharmaceuticals | Renal (advanced) | NCT04895748 | 1, 1b (NR, OL) |
| A2AR | NIR178 +/− Spartalizumab (mAb against PD-1 | Novartis Pharmaceuticals | Solid tumor, NHL | NCT03207867 | 2 (NR, OL) |
| A2AR | PBF -509 | Palobiofarma SL | NA (safety assessment) | NCT01691924 | 1 (R) |
| A2AR | PBF -509 | Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau | Cancer (general) | NCT02111330 | 1 (R, DB, PC) |
| A2AR | Ciforadenant + daratumumab (mAb against CD38) | Corvus Pharmaceuticals, Inc. | Multiple Myeloma | NCT04280328 | 1 (OL) |
| A2AR | TT-10 | Tarus Therapeutics | Renal, prostate, NSCLC (AST) | NCT04969315 | 1, 2 (OL) |
| A2BR | TT-4 | Tarus Therapeutics | Gastrointestinal, hepatocellular, prostate | NCT04976660 | 1, 2 (OL) |
| A2AR/A2BR | Arm 1: AB928/Etrumadenant + zimberelimab (mAb against PD-1) + enzalutamide Arm 2: AB928/Etrumadenant + zimberelimab (mAb against PD-1) + docetaxel |
Arcus Biosciences, Inc. | Prostate (advanced/incurable) | NCT04381832 | 1, 2 (R, OL) |
| A2AR/A2BR | AB928/Etrumadenant (dual antagonist) + zimberelimab (mAb against PD-1) | Arcus Biosciences, Inc. | Advanced malignancies | NCT03629756 | 1 (NR, OL) |
| A2AR/A2BR | AB928/Etrumadenant (dual antagonist) + Cisplatin/Radiation Therapy + Zimberelimab (mAb against PD-1) | Jennifer Choe in collaboration with Arcus Biosciences Inc | Head and neck | NCT04892875 | 1 (NR, OL) |
| A2AR/A2BR | Arm 1. AB928/Etrumadenant (dual antagonist) + zimberelimab (mAb against PD-1) + standard chemotherapeutic regime (mFOLFOX-6 + bevacizumab) Arm 2: AB928/Etrumadenant zimberelimab (mAb against PD-1) + AB680 (CD73 inhibitor) |
Arcus Biosciences Inc. | Colon (metastatic) | NCT04660812 | 1, 2 (R, OL) |
| A2AR/A2BR | AB928/Etrumadenant (dual antagonist) + Carboplatin and Pemetrexed +/− Zimberelimab (mAb against PD-1) | Arcus Biosciences Inc. | Lung | NCT03846310 | 1 (NR, OL) |
| A2AR/A2BR | Arm A: AB928/Etrumadenant (dual antagonist) + Pegylated liposomal doxorubicin (PLD) Arm B: Etrumadenant + nanoparticle albumin-bound paclitaxel (NP) Arm C: Etrumadenant +PLD + IPI-549 (phosphoinositide-3-kinase-gamma inhibitor) |
Arcus Biosciences Inc. | Breast (TN) or gynecologic | NCT03719326 | 1 (NR, OL) |
| A2AR/A2BR | AB928/Etrumadenant (dual antagonist) + mFOLFOX | Arcus Biosciences Inc. | Gastrointestinal | NCT03720678 | 1 (NR, OL) |
| A2BR | PBF-1129 | Palobiofarma SL | NSCLC | NCT03274479 | 1 (NR, OL) |
| A2AR | Arm 1: AZD4635 + Durvalumab (mAb against PD-L1) Arm 2: AZD4635 + Oleclumab (mAb against CD73) Arm 3: AZD4635 + Durvalumab + Oleclumab |
AstraZeneca | Prostate | NCT04089553 | 1, 2 (NR, OL) |
| A2BR | TT-4 | Tarus Therapeutics | Gastrointestinal, hepatocellular, prostate | NCT04976660 | 1, 2 (OL) |
| A2BR | TT-4 | Tarus Therapeutics | Gastrointestinal, hepatocellular, prostate | NCT04976660 | 1, 2 (OL) |
| A2BR | TT-4 | Tarus Therapeutics | Gastrointestinal, hepatocellular, prostate | NCT04976660 | 1, 2 (OL) |
* Only the target related to AR type is indicated. Abbreviations: AST: Advanced solid tumors; mAb or mab: monoclonal antibody; DB: Double blind; NA: Not applicable (safety assessment in healthy individuals); MC: multicenter; NHL: Non-Hodgkin lymphoma; NSCLC: Non-Small Cell Lung Cancer; NR: non-randomized; PC: Placebo-controlled; R: randomized; OL: Open label; TN: triple negative.